1
|
Traoré L, Savadogo M, Zouré AA, Kiendrebeogo TI, Soudre FMBTB, Dabre S, Traore ADD, Adico MDW, Lare T, Ouedraogo TWC, Ouedraogo RA, Ouattara AK, Yelemkoure ET, Sawadogo AY, Zongo N, Bambara HA, Nadembega CW, Djigma FW, Simpore J. Carrying SNP rs17506395 (T > G) in TP63 gene and CCR5Δ32 mutation associated with the occurrence of breast cancer in Burkina Faso. Open Life Sci 2024; 19:20220847. [PMID: 38585642 PMCID: PMC10998675 DOI: 10.1515/biol-2022-0847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Revised: 01/25/2024] [Accepted: 03/05/2024] [Indexed: 04/09/2024] Open
Abstract
Genetic alterations in the TP63 (GenBank: NC_000003.12, ID: 8626) and CCR5 (receptor 5 chemokine co-receptor) (GenBank: NC_000003.12, ID: 1234) genes may increase the risk of developing breast cancer. The aim of this study was to investigate the probable involvement of polymorphisms rs17506395 in the TP63 (tumour protein 63) gene and the CCR5Δ32 mutation in the occurrence of breast cancer in Burkina Faso. This case-control study included 72 patients and 72 controls. Genotyping of SNP rs17506395 (TP63) was performed by polymerase chain reaction-restriction fragment length polymorphism, and genotyping of the CCR5Δ32 mutation was performed by allele-specific oligonucleotide polymerase chain reaction. For SNP rs17506395 (TP63), the genotypic frequencies of wild-type homozygotes (TT) and heterozygotes (TG) were, respectively, 27.72 and 72.22% in cases and 36.11 and 63.89% in controls. No mutated homozygotes (GG) were observed. For the CCR5Δ32 mutation, the genotypic frequencies of wild-type homozygotes (WT/WT) and heterozygotes (WT/Δ32) were 87.5 and 13.5%, respectively, in the cases and 89.29 and 10.71%, respectively, in the controls. No mutated homozygotes (Δ32/Δ32) were observed. None of the polymorphisms rs17506395 of the TP63 gene (OR = 1.47, 95% CI = 0.69-3.17, P = 0.284) and the CCR5Δ32 mutation (OR = 1.32, 95% CI = 0.46-3.77; P = 0.79) were associated with the occurrence of breast cancer in this study.
Collapse
Affiliation(s)
- Lassina Traoré
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Mousso Savadogo
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Abdou Azaque Zouré
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
- Biomedical Research Laboratory (LaReBio), Biomedical and Public Health Department, Health Sciences Research Institute (IRSS/CNRST), 03 BP 7192Ouaga 03, Burkina Faso
| | - Touwendpoulimdé Isabelle Kiendrebeogo
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Fabienne Marie B. T. B. Soudre
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Laboratory Department, University Hospital Centre-Yalgado OUEDRAOGO, Joseph KI-ZERBO University, UFR/SDS, 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso
| | - Soayebo Dabre
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Aida Djé Djénéba Traore
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Marc Donald Wilfried Adico
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Tilate Lare
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Teega-Wendé Clarisse Ouedraogo
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Rogomenoma Alice Ouedraogo
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
- Gaoua University Centre, NAZI BONI University, 01 BP 1091, Bobo-Dioulasso 01, Burkina Faso
| | - Abdoul Karim Ouattara
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
- Manga University Centre, Norbert ZONGO University, Koudougou, Burkina Faso
| | - Edwige T. Yelemkoure
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Alexis Yobi Sawadogo
- Gynecology Department, Yalgado Ouédraogo University Hospital, UFR/SDS, 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso
| | - Nayi Zongo
- Department of Surgery, Visceral and Digestive Surgery Service, Yalgado Ouédraogo University Hospital, Joseph KI-ZERBO University, UFR/SDS 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso
| | - Hierrhum Aboubacar Bambara
- Oncology Department, University Hospital Centre-BOGODOGO, Joseph KI-ZERBO University, UFR/SDS, 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso
| | - Christelle W. Nadembega
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Florencia W. Djigma
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Jacques Simpore
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| |
Collapse
|
2
|
Zohoncon TM, Zouré AA, Ouattara AK, Zida FB, Belemgnégré M, Ouedraogo P, Simpore J. Prevalence and patterns of chromosomal abnormalities in patients suspected of genetic disorders: insights from a study in Ouagadougou, Burkina Faso. Mol Biol Rep 2023; 50:9239-9247. [PMID: 37814033 DOI: 10.1007/s11033-023-08752-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2023] [Accepted: 08/09/2023] [Indexed: 10/11/2023]
Abstract
BACKGROUND Chromosomal abnormalities contribute significantly to human morbidity and mortality, leading to various pathologies. This study aimed to assess the prevalence of chromosomal abnormalities among patients suspected of genetic disorders in Ouagadougou, Burkina Faso. METHODS AND RESULTS A descriptive cross-sectional study was conducted from January 1, 2018, to July 16, 2021, involving patients from different university hospitals in Ouagadougou. Blood samples were collected at Hôpital Saint Camille de Ouagadougou (HOSCO) and sent to the Cerba laboratory in France for cytogenetic analysis. A total of 61 cases with suspected genetic disorders were referred for cytogenetic examination. The average age of the patients was 26.81 years ± 18.92, ranging from 1 month to 68 years. Among the cases, 37 (60.65%) exhibited chromosomal abnormalities. Structural abnormalities were the most prevalent (78.38%), while number anomalies accounted for 21.62% of the cases. Chronic myeloid leukemia was detected in 59.45% of cases, followed by free and homogeneous trisomy 21 (18.91%) and sexual inversion (8.10%). Additionally, one case each of Turner syndrome and Klinefelter syndrome were identified. CONCLUSION This this study revealed a high frequency of chromosomal abnormalities, with a predominance of structural abnormalities, among patients suspected of genetic disorders in Ouagadougou. The findings emphasize the significance of genetic evaluation and counseling services in the region, particularly for autosomal abnormalities.
Collapse
Affiliation(s)
- Théodora Mahoukèdè Zohoncon
- Hôpital Saint Camille de Ouagadougou (HOSCO), Ouagadougou, 09 BP 444, Burkina Faso.
- Faculté des Sciences de la Santé, Université Saint Thomas d'Aquin (USTA), Ouagadougou, 06 BP 10212, Burkina Faso.
| | - Abdou Azaque Zouré
- Département de biomédecine et de santé publique, Institut de recherche en sciences de la santé (IRSS/CNRST), Ouagadougou, 03 BP 7192, Burkina Faso
| | - Abdoul Karim Ouattara
- Université Norbert Zongo/Centre Universitaire de Manga, Koudougou, BP 376, Burkina Faso
| | - Franck Bienvenu Zida
- Faculté des Sciences de la Santé, Université Saint Thomas d'Aquin (USTA), Ouagadougou, 06 BP 10212, Burkina Faso
| | - Marius Belemgnégré
- Hôpital Saint Camille de Ouagadougou (HOSCO), Ouagadougou, 09 BP 444, Burkina Faso
| | - Paul Ouedraogo
- Hôpital Saint Camille de Ouagadougou (HOSCO), Ouagadougou, 09 BP 444, Burkina Faso
| | - Jacques Simpore
- Hôpital Saint Camille de Ouagadougou (HOSCO), Ouagadougou, 09 BP 444, Burkina Faso
- Faculté des Sciences de la Santé, Université Saint Thomas d'Aquin (USTA), Ouagadougou, 06 BP 10212, Burkina Faso
| |
Collapse
|
3
|
Ouedraogo AR, Traoré L, Ouattara AK, Ouedraogo AR, Zongo SV, Savadogo M, Lallogo TD, Sombie HK, Sorgho PA, Ouedraogo TWC, Djigma FW, Lamien AS, Yonli AT, Lompo OM, Simporé J. Association of HLA-DRB1*11 and HLA-DRB1*12 gene polymorphism with COVID-19 in Burkina Faso. BMC Med Genomics 2023; 16:246. [PMID: 37845715 PMCID: PMC10577973 DOI: 10.1186/s12920-023-01684-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Accepted: 10/03/2023] [Indexed: 10/18/2023] Open
Abstract
BACKGROUND The clinical manifestations of coronavirus disease (COVID-19) can vary widely, ranging from asymptomatic to severe, and may be influenced by the host genetic background. The aim of the present study was to determine the frequencies of HLA-DRB1*11 and HLA-DRB1*12 allele polymorphisms and their associations with COVID-19. METHODS In this cross-sectional study, 198 subjects were enrolled, including 150 COVID-19 positive cases and 48 subjects who tested negative for COVID-19. Participants were recruited from the emergency, intensive care, and infectious diseases departments of the Bogodogo Centre University Hospital (CHU-B) or the routine laboratory of Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA). Genomic DNA was extracted from nasopharyngeal swabs samples and multiplex PCR-SSP was used to detect the HLA-DRB1*11 and HLA-DRB1*12 alleles. The study was approved by CERS (№ 2021-02-033). RESULTS The positive cases were categorized into 38 asymptomatic (CC+), 60 symptomatic (NC+), and 52 severe cases (SC+). Females were more frequent in the overall study population (53.0%, 105/198) as well as in the negative group's CC- (68.75%, 33/48) and SC+ (57.69%, 30/52 negative groups, whereas males were more frequent in the CC+ (63.16%, 24/38) and NC+ (53.33%, 32/60) groups. The highest mean age was observed in the SC + group. A frequency of 19.19% (38/198) and 14.65% (29/198) was found for the HLA-DRB1*11 and HLA-DRB1*12 alleles, respectively. Individuals carrying the HLA-DRB1*11 allele had an approximately sixfold higher risk of asymptomatic SARS-CoV-2 infection (OR = 5.72 [1.683-19.442], p = 0.005) based on the association analysis. CONCLUSIONS Altogether, the present study reports high frequency of HLA-DRB1*11 and HLA-DRB1*12 alleles within a population from Ouagadougou, Burkina Faso. The results suggest that individuals carrying the HLA-DRB1*11 allele are more susceptible to COVID-19 infection but may not display symptoms.
Collapse
Affiliation(s)
- Alfred Rakissida Ouedraogo
- Laboratoire de Morphologie et Organogénèse (LAMO), Université Joseph KI-ZERBO, UFR/SDS, Ouagadougou 01, 01 BP 7021, Burkina Faso
| | - Lassina Traoré
- Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Ouagadougou 01, 01 BP 7021, Burkina Faso
- Université Norbert ZONGO - Centre Universitaire de Manga, BP 376, Koudougou, Burkina Faso
| | - Abdoul Karim Ouattara
- Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Ouagadougou 01, 01 BP 7021, Burkina Faso
- Université Norbert ZONGO - Centre Universitaire de Manga, BP 376, Koudougou, Burkina Faso
| | - Alexis Rakiswende Ouedraogo
- Laboratoire de Morphologie et Organogénèse (LAMO), Université Joseph KI-ZERBO, UFR/SDS, Ouagadougou 01, 01 BP 7021, Burkina Faso
| | - Sidnooma Véronique Zongo
- Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Ouagadougou 01, 01 BP 7021, Burkina Faso
| | - Mousso Savadogo
- Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Ouagadougou 01, 01 BP 7021, Burkina Faso
| | - Tatiana Doriane Lallogo
- Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Ouagadougou 01, 01 BP 7021, Burkina Faso
| | - Herman Karim Sombie
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Pegdwendé Abel Sorgho
- Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Ouagadougou 01, 01 BP 7021, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Teega-Wendé Clarisse Ouedraogo
- Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Ouagadougou 01, 01 BP 7021, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Ouagadougou 01, 01 BP 7021, Burkina Faso.
| | - Assita Sanou Lamien
- Laboratoire de Morphologie et Organogénèse (LAMO), Université Joseph KI-ZERBO, UFR/SDS, Ouagadougou 01, 01 BP 7021, Burkina Faso
| | - Albert Théophane Yonli
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Olga Mélanie Lompo
- Laboratoire de Morphologie et Organogénèse (LAMO), Université Joseph KI-ZERBO, UFR/SDS, Ouagadougou 01, 01 BP 7021, Burkina Faso
| | - Jacques Simporé
- Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Ouagadougou 01, 01 BP 7021, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| |
Collapse
|
4
|
Simpore A, Bazie BV, Zoure AA, Ouattara AK, Compaore RT, Kiba-Koumare A, Yooda PA, Djigma FW, Sombié HK, Bisseye C, Simpore J. Performance of Molecular Tests in the Diagnosis of Syphilis From 2009 to 2019: A Systematic Review and Meta-Analysis. Sex Transm Dis 2022; 49:469-476. [PMID: 35320152 DOI: 10.1097/olq.0000000000001633] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Syphilis continues to be a public health problem, and its diagnosis still has limitations. Molecular diagnosis provides an alternative for rapid and effective management. The objective is to determine the accuracy of tests in the molecular diagnosis of syphilis. METHODS We searched PubMed and Web of Sciences for articles related to molecular detection of syphilis from January 1, 2009, to December 31, 2019. The bivariate Reitsma model and the hierarchical receiver operating characteristic curve model were used to evaluate the diagnostic performance of molecular tests at a 95% confidence interval. A subgroup meta-analysis was performed to explore sources of heterogeneity. RESULTS Forty-seven articles were identified for qualitative synthesis, of which 23 met the inclusion criteria for meta-analysis. The pooled sensitivities in conventional polymerase chain reaction (PCR) and real-time PCR were 77.52 (59.50-89.01) and 68.43 (54.96-79.39), respectively. The pooled specificities were 98.00 (90.73-99.59) and 98.84 (97.55-99.46), respectively. Ulcer samples had a better performance (sensitivity of 79.88 [69.00-87.62] and specificity of 98.58 [97.25-99.27]), and the major target genes were the polymerase A gene and tpp47 gene. CONCLUSIONS Our work showed that conventional PCR was more widely used than real-time PCR in the diagnosis of syphilis, and ulcers were the best specimens. Sample types and target genes are factors that may influence the quality of the different tests. These results could provide evidence for further work in the direction of providing a more efficient diagnostic test.
Collapse
Affiliation(s)
| | | | | | - Abdoul Karim Ouattara
- From the Laboratory of Molecular Biology and Genetics (LABIOGENE), Joseph KI-ZERBO University
| | | | - Alice Kiba-Koumare
- National Center for Blood Transfusion in Burkina Faso (CNTS), Ouagadougou, Burkina Faso
| | - Paul A Yooda
- From the Laboratory of Molecular Biology and Genetics (LABIOGENE), Joseph KI-ZERBO University
| | | | | | - Cyrille Bisseye
- Laboratory of Molecular and Cellular Biology (LABMC), University of Science and Technology of Masuku (USTM), Franceville, Gabon
| | | |
Collapse
|
5
|
Kiendrebeogo IT, Zoure AA, Zongo FI, Ouattara AK, Ouedraogo MN, Amegnona J, Yonli AT, Bayala B, Zongo N, Bambara AH, Sawadogo AY, Zohoncon TM, Obiri-Yeboah D, Simpore J. Mutations in exon 11 (11.1 and 11.2) of the <em>BRCA1</em> gene and risk factors for breast cancer in Burkina Faso. J Public Health Afr 2022; 13:1921. [PMID: 35720803 PMCID: PMC9202467 DOI: 10.4081/jphia.2022.1921] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Accepted: 11/28/2021] [Indexed: 11/23/2022] Open
Abstract
Breast cancer is the leading cause of death among women in both developed and developing countries. It is multifactorial, including genetic predispositions such as oncogenic mutations on BRCA1 and 2 genes. The objectives of the present study were to identify oncogenic mutations in exon 11 of the BRCA1 gene and to determine the risk factors for breast cancer among women population in Burkina Faso. This study involved 100 women, including 50 cases of breast cancer and 50 controls (no clinical signs and no family history of breast cancer or other cancers). Mutations in the BRCA1 gene were detected by PCR using sequence primers specific for exon 11 fragments (11.1 and 11.2). In our study population, age (OR=22.40; CI: 4.33-115.82; p<0.001) and obesity (OR=4.23; CI: 1.64-10.92; p=0.003) were risk factors while multiparity was a protective factor for breast cancer (OR=0.35; CI: 0.15-0.81; p=0.02). A mutation was found on both fragments 11.1 and 11.2 of the BRCA1 gene exon 11 in 04/50 (8.0 %) of patients. No mutations were observed in controls. The present study revealed high frequency of oncogenic mutations in exon 11 fragments (11.1 and 11.2) of the BRCA1 gene. These mutations on exon 11 are and involved in the occurrence of breast cancer in our population. Age and obesity were also risk factors for breast cancer among women population in Burkina Faso.
Collapse
|
6
|
Ilboudo DP, Zohoncon TM, Hien YE, Ouattara AK, Traore L, Ouermi D, Djigma WF, Nadembega CM, Belemgnegre M, Ouedraogo P, Karou DS, Traore Y, Simpore J. Dengue Immunological Markers Evolution at Saint Camille Hospital in Ouagadougou (HOSCO) Burkina Faso. Pak J Biol Sci 2022; 25:254-262. [PMID: 35234016 DOI: 10.3923/pjbs.2022.254.262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
<b>Background and Objective:</b> Dengue is a remerging vector-borne viral disease in Burkina Faso since the outbreak of 2013 and requires special attention from health authorities. This study reports the prevalence of dengue fever serological markers (NS1Ag, IgM and IgG) and infection dynamic from January, 2018 to December, 2020 among patients tested for dengue infection at Saint Camille Hospital of Ouagadougou (HOSCO). <b>Materials and Methods:</b> The study population consisted of 6414 patients aged 0-97 years. Dengue virus infection was detected in serum or plasma using the SD bioline dengue duo rapid detection kit. <b>Results:</b> The prevalence of dengue NS1Ag was 2.25% (45/2003), 18.43% (501/2719) and 2.42% (38/1569) in the study population in 2018, 2019 and 2020, respectively. The age groups over 50 years and 15-20 years were significantly more infected compared to the group 21-30 years respectively in 2019 (p = 0.030) and 2020 (p = 0.035). Patients tested positive for at least one of these markers (NSlAg, IgG and IgM) represented 26.01% (521/2003) and 38.98% (1060/2719). The peak of infection during 2018 and 2019 was observed between October and November. The present study reports a high seroprevalence of acute dengue virus infection. The presence of NS1Ag, IgM and IgG in patients suggests an active circulation of the dengue virus in Ouagadougou. <b>Conclusion:</b> Data shows recurrent outbreaks of dengue infection in our country need strong surveillance and a suitable and affordable diagnostic system to clarify the burden, pinpoint the risk factors and for better case management.
Collapse
|
7
|
Yelemkoure ET, Yonli AT, Sombie HK, Tao I, Zouré AA, Ouattara AK, Sorgho AP, Zongo AW, Zeba MTA, Kiendrebeogo IT, Bado P, Kabré MK, Zohoncon TM, Djigma FW, Obiri-Yeboah D, Simpore J. Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso. Intervirology 2021; 65:151-159. [PMID: 34583364 PMCID: PMC9501785 DOI: 10.1159/000519848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 09/23/2021] [Indexed: 11/19/2022] Open
Abstract
Introduction Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV seroprevalence, characterize circulating genotypes, and monitor HCV viral loads in patients under treatment with antivirals. Methods A total of 4,124 individuals and 167 patients in the pre-therapy program were recruited. The “SD Bioline HCV” kit was used for rapid screening of anti-HCV antibodies. Viral load and genotyping were performed in 167 HCV patients on antivirals using the “Iontek HCV Quant” and “Iontek genotyping” kits. Results Prevalence of HCV was 1.65% (68/4,124), and the median viral load of participants was 5.37 log10/mL (1.32–7.67 log10/mL). Genotype 2 was predominant with a frequency of 86.23% (144/167) and appeared to be more active with higher viral load compared to 13.77% (23/167) for genotype 1 (p < 0.001). After 24 weeks of pan-genotypic direct-acting antivirals, such as sofosbuvir/daclatasvir and sofosbuvir/velpatasvir, the viral loads of all patients became undetectable. Conclusion The responses to antivirals by the circulating genotypes indicate that the results are very satisfactory. Therefore, the prevalence of HCV in the population can be reduced through identification of cases and treatment.
Collapse
Affiliation(s)
- Edwige T Yelemkoure
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Albert T Yonli
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Hermann K Sombie
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Issoufou Tao
- Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso.,Institute of Sciences, Ouagadougou, Burkina Faso
| | - Abdou Azaque Zouré
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Department of Biomedical and Public Heath, Institute for Research in Health Sciences (IRSS/CNRST), Ouagadougou, Burkina Faso
| | - Abdoul Karim Ouattara
- Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso.,University Center of Manga, Norbert ZONGO University, Koudougou, Burkina Faso
| | - Abel P Sorgho
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Arsène W Zongo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Moctar T A Zeba
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Isabelle T Kiendrebeogo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Prosper Bado
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Madeleine K Kabré
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Théodora M Zohoncon
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,University Saint Thomas d'Aquin, Faculty of Medicine, Ouagadougou, Burkina Faso
| | - Florencia W Djigma
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso.,Department of Microbiology and Immunology, University of Cape Coast, School of Medical Sciences, Cape Coast, Ghana
| | - Jacques Simpore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso.,University Saint Thomas d'Aquin, Faculty of Medicine, Ouagadougou, Burkina Faso
| |
Collapse
|
8
|
Millogo M, Soubeiga ST, Bazie BVJT, Zohoncon TM, Ouattara AK, Yonli AT, Simpore J. Disputed paternity presumption in Burkina Faso: determination of the biological fathers of children using ABO-rhesus/hemoglobin electrophoresis and STR assays. J Genet Eng Biotechnol 2021; 19:130. [PMID: 34459998 PMCID: PMC8405726 DOI: 10.1186/s43141-021-00221-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 07/30/2021] [Indexed: 12/04/2022]
Abstract
BACKGROUND In resource-limited countries, ABO, HLA, MNS, Kells, and hemoglobin electrophoresis are classic tests for the resolution of paternity disputes due to their affordable cost. The limitations of these tests in cases of disputed paternity require the use of Short Tandem Repeats (STR) for their certification. This study aimed to determine the biological fathers of children using ABO-rhesus/hemoglobin electrophoresis and STR assays in Burkina Faso, West Africa. RESULTS Of the fourteen trios studied, the ABO-rhesus/hemoglobin electrophoresis analysis revealed ten probable inclusion cases, three exclusion cases, and one undetermined paternity. DNA STR analysis found five inclusions of paternity out of the ten probable inclusions with ABO-rhesus/hemoglobin electrophoresis assay versus nine exclusions of paternity. CONCLUSION This study showed that the implementation of the analysis of short tandem repeat is required to resolve increasing disputed filiation cases in Burkina Faso.
Collapse
Affiliation(s)
- Missa Millogo
- Direction of Scientific and Technical Police, Ouagadougou, Burkina Faso
- Laboratory of Molecular Biology and Genetics (LABIOGENE) of University Joseph Ki-Zerbo, P.O. 03 BOX, 7021 Ouaga 03, Ouagadougou, Burkina Faso
| | - Serge Theophile Soubeiga
- Laboratory of Molecular Biology and Genetics (LABIOGENE) of University Joseph Ki-Zerbo, P.O. 03 BOX, 7021 Ouaga 03, Ouagadougou, Burkina Faso.
- Biomolecular Research Centre Pietro Annigoni (CERBA)), P.O. 01 BOX 364, Ouagadougou, Ouaga 01, Burkina Faso.
- Research Institute of Health Sciences (IRSS)), P.O. 03. BOX 7192, Ouagadougou, Ouaga 03, Burkina Faso.
| | - Bapio Valerie Jean Telesphore Bazie
- Laboratory of Molecular Biology and Genetics (LABIOGENE) of University Joseph Ki-Zerbo, P.O. 03 BOX, 7021 Ouaga 03, Ouagadougou, Burkina Faso
- Biomolecular Research Centre Pietro Annigoni (CERBA)), P.O. 01 BOX 364, Ouagadougou, Ouaga 01, Burkina Faso
- Research Institute of Applied and Technical Sciences (IRSAT)), P.O. 03 BOX 7047, Ouagadougou, Ouaga 03, Burkina Faso
| | - Theodora Mahoukede Zohoncon
- Laboratory of Molecular Biology and Genetics (LABIOGENE) of University Joseph Ki-Zerbo, P.O. 03 BOX, 7021 Ouaga 03, Ouagadougou, Burkina Faso
- Biomolecular Research Centre Pietro Annigoni (CERBA)), P.O. 01 BOX 364, Ouagadougou, Ouaga 01, Burkina Faso
- University of Saint Thomas d'Aquin (USTA)), P.O. 06 BOX 10212, Ouagadougou, Ouaga 06, Burkina Faso
| | - Abdoul Karim Ouattara
- Laboratory of Molecular Biology and Genetics (LABIOGENE) of University Joseph Ki-Zerbo, P.O. 03 BOX, 7021 Ouaga 03, Ouagadougou, Burkina Faso
- Biomolecular Research Centre Pietro Annigoni (CERBA)), P.O. 01 BOX 364, Ouagadougou, Ouaga 01, Burkina Faso
| | - Albert Theophane Yonli
- Laboratory of Molecular Biology and Genetics (LABIOGENE) of University Joseph Ki-Zerbo, P.O. 03 BOX, 7021 Ouaga 03, Ouagadougou, Burkina Faso
- Biomolecular Research Centre Pietro Annigoni (CERBA)), P.O. 01 BOX 364, Ouagadougou, Ouaga 01, Burkina Faso
| | - Jacques Simpore
- Laboratory of Molecular Biology and Genetics (LABIOGENE) of University Joseph Ki-Zerbo, P.O. 03 BOX, 7021 Ouaga 03, Ouagadougou, Burkina Faso
- Biomolecular Research Centre Pietro Annigoni (CERBA)), P.O. 01 BOX 364, Ouagadougou, Ouaga 01, Burkina Faso
- University of Saint Thomas d'Aquin (USTA)), P.O. 06 BOX 10212, Ouagadougou, Ouaga 06, Burkina Faso
| |
Collapse
|
9
|
Minoungou GL, Diop M, Dakouo M, Ouattara AK, Settypalli TBK, Lo MM, Sidibe S, Kanyala E, Kone YS, Diallo MS, Ouedraogo A, Coulibaly K, Ouedraogo V, Sow I, Niang M, Achenbach JE, Wade A, Unger H, Diallo A, Cattoli G, Lamien CE, Simpore J. Molecular characterization of African Swine fever viruses in Burkina Faso, Mali, and Senegal 1989-2016: Genetic diversity of ASFV in West Africa. Transbound Emerg Dis 2021; 68:2842-2852. [PMID: 34323385 DOI: 10.1111/tbed.14240] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Revised: 06/12/2021] [Accepted: 07/13/2021] [Indexed: 11/26/2022]
Abstract
African swine fever (ASF) has been endemic in sub-Saharan Africa since the 1960s. Following its introduction in Senegal, in 1957, ASF steadily progressed through West Africa, reaching Burkina Faso in 2003, and later Mali in 2016. Despite the heavy burden of disease on pig production, little information is available on the genetic diversity of Africa swine fever virus (ASFV) in Burkina Faso, Mali and Senegal. Here, we used real-time PCR ASFV to detect the ASFV genome in samples collected between 1989 and 2016, in Burkina Faso, Mali and Senegal, and conventional approaches for isolate characterization. The C-terminal end of the p72 protein gene, the full E183L gene and the central variable region (CVR) within the B602L gene in ASFV genome were sequenced and compared to publicly available sequences. ASFV genome was found in 27 samples, 19 from Burkina Faso, three from Mali and five from Senegal. The phylogenetic analyses showed that all viruses belong to genotype I, with the ASFVs from Burkina Faso and Mali grouping with genotype Ia and ASFV serogroup 4, and those from Senegal with genotype Ib and the ASFV serogroup 1. The analysis of the CVR tetrameric tandem repeat sequences (TRS) showed four TRS variants in Burkina Faso, two in Senegal and one in Mali. The three countries did not share any common TRS, and all CVRs of this study differed from previously reported CVRs in West Africa, except for Senegal. Three of the five isolates from Senegal fully matched with the CVR, p72 and p54 sequences from ASFV IC96 collected during the 1996 ASF outbreak in Ivory Coast. This study shows the spread of the same ASFV strains across countries, highlighting the importance of continuous monitoring of ASFV isolates. It also calls for an urgent need to establish a regional plan for the control and eradication of ASF in West Africa.
Collapse
Affiliation(s)
- Germaine L Minoungou
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Joseph KI-ZERBO, Ouagadougou, Burkina Faso.,Laboratoire National d'Elevage (LNE), Ouagadougou, Burkina Faso
| | - Mariame Diop
- Laboratoire National de l'Elevage et de Recherches Vétérinaires (LNERV), Institut Sénégalais de Recherches Agricoles (ISRA), Dakar, Sénégal
| | | | - Abdoul Karim Ouattara
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Joseph KI-ZERBO, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Tirumala Bharani K Settypalli
- Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Modou M Lo
- Laboratoire National de l'Elevage et de Recherches Vétérinaires (LNERV), Institut Sénégalais de Recherches Agricoles (ISRA), Dakar, Sénégal
| | | | - Estelle Kanyala
- Direction de la Santé Animale (DSA), Ouagadougou, Burkina Faso
| | | | | | - Anne Ouedraogo
- Laboratoire National d'Elevage (LNE), Ouagadougou, Burkina Faso
| | | | | | - Ibrahim Sow
- Laboratoire Central Vétérinaire (LCV), Bamako, Mali
| | - Mamadou Niang
- Laboratoire Central Vétérinaire (LCV), Bamako, Mali.,Emergency Center for Transboundary Animal Diseases (ECTAD), Regional Office for Africa (RAF), Food and Agriculture Organization of the United Nations (FAO), Accra, Ghana
| | | | - Abel Wade
- National Veterinary Laboratory (LANAVET), Garoua, Cameroon
| | - Hermann Unger
- Animal Production and Health Section, Joint FAO/IAEA Division for Nuclear Applications in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna International Centre, Vienna, Austria
| | - Adama Diallo
- Laboratoire National de l'Elevage et de Recherches Vétérinaires (LNERV), Institut Sénégalais de Recherches Agricoles (ISRA), Dakar, Sénégal.,Cirad, UMR CIRAD INRA, Animal, Santé, Territoires, Risques et Ecosystèmes (ASTRE), Campus International de Baillarguet, Montpellier, France
| | - Giovanni Cattoli
- Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Charles Euloge Lamien
- Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Jacques Simpore
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Joseph KI-ZERBO, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| |
Collapse
|
10
|
Sombié HK, Tchelougou D, Ouattara AK, Kologo JK, Sorgho PA, Somda D, Yaméogo S, Zongo AW, Kiendrebeogo IT, Adoko ETHD, Yonli AT, Djigma FW, Zabsonré P, Millogo H, Simporé J. Glutathione S-transferase M1 and T1 genes deletion polymorphisms and blood pressure control among treated essential hypertensive patients in Burkina Faso. BMC Res Notes 2021; 14:244. [PMID: 34193266 PMCID: PMC8243756 DOI: 10.1186/s13104-021-05658-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 06/17/2021] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE Glutathione S-transferases have been associated with experimental resistance to some drugs. The present study investigated the factors associated with blood pressure control in patients with essential hypertension, especially the role of GSTT1 and GSTM1 genes polymorphisms. This cross-sectional study in Burkina Faso consisted of 200 patients with essential hypertension and under treatment. RESULTS In the present study, 57.5% (115/200) of patients had their hypertension under control. No statistically significant difference was found between controlled and uncontrolled groups for anthropometric and biochemical parameters as well as for GSTT1 or GSTM1 gene polymorphisms (all p > 0.05). Current alcohol consumption (OR = 3.04; CI 1.88-6.13; p < 0.001), Physical inactivity (OR = 3.07; CI 1.71-5.49; p < 0.001), severe hypertension before any treatment (Grade III [OR = 3.79; CI 2.00-7.17; p < 0.001]) and heart damage (OR = 3, 14; CI 1.59-6.02; p < 0.001) were statistically more frequent in uncontrolled essential hypertensive patients than controlled hypertensive patients.
Collapse
Affiliation(s)
- Herman Karim Sombié
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Daméhan Tchelougou
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Abdoul Karim Ouattara
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso. .,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso. .,CERBA/LABIOGENE; University Joseph Ki-Zerbo, 01 BP 364, Ouagadougou 01, Burkina Faso.
| | - Jonas Koudougou Kologo
- Saint Camille Hospital of Ouagadougou (HOSCO), 01 P.O. Box 444, Ouagadougou 01, Burkina Faso.,University Hospital Center-Yalgado Ouédraogo (CHUYO), 01 P.O. Box 676, Ouagadougou, Burkina Faso
| | - Pegdwendé Abel Sorgho
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Dogfunianalo Somda
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Sakinata Yaméogo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Arsène Wendpagnangdé Zongo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Isabelle Touwendpoulimdé Kiendrebeogo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | | | - Albert Théophane Yonli
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Patrice Zabsonré
- University Hospital Center-Yalgado Ouédraogo (CHUYO), 01 P.O. Box 676, Ouagadougou, Burkina Faso
| | - Hassanata Millogo
- University Hospital Center-Yalgado Ouédraogo (CHUYO), 01 P.O. Box 676, Ouagadougou, Burkina Faso
| | - Jacques Simporé
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso.,Saint Camille Hospital of Ouagadougou (HOSCO), 01 P.O. Box 444, Ouagadougou 01, Burkina Faso.,Faculty of Medicine, University Saint Thomas d'Aquin, P.O. Box 10212, Ouagadougou, Burkina Faso
| |
Collapse
|
11
|
Bado P, Djigma FW, Zohoncon TM, Obiri-Yeboah D, Traoré EMA, Ouattara AK, Ouedraogo TWC, Bello SOT, Setor MA, Traore IMA, Horo A, Kouakou KP, Yonli TA, Ouedraogo C, Simpore J. Erratum to “Polymorphism of MMP1 and MMP3 promoter regions and HR-HPV infection in women from Burkina Faso and Côte d‘Ivoire”. Biomol Concepts 2020; 11:142. [DOI: 10.1515/bmc-2020-0013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 06/05/2020] [Indexed: 11/15/2022] Open
|
12
|
Ouedraogo RA, Zohoncon TM, Traore IMA, Ouattara AK, Guigma SP, Djigma FW, Obiri-Yeboah D, Ouedraogo C, Simpore J. Genotypic distribution of human oncogenic papillomaviruses in sexually active women in Burkina Faso: Central, Central-Eastern and Hauts-Bassins regions. Biomol Concepts 2020; 11:125-136. [PMID: 32417758 DOI: 10.1515/bmc-2020-0011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 04/15/2020] [Indexed: 11/19/2022] Open
Abstract
Objective this study was conducted to determine the distribution of high-risk human papillomavirus (HR-HPV) genotypes in women in the general population of three regions of Burkina Faso. Method This multicenter, descriptive cross-sectional study involved 1321 sexually active women in five cities in three regions of Burkina Faso: Central, Central-Eastern and Hauts-Bassins regions. After collection of endocervical specimens, pre-cervical lesions were screened by visual inspection with acetic acid and lugol (VIA / VILI). HR-HPV genotypes were characterized by multiplex real-time PCR after extraction of viral DNA. Results The mean age of women was 31.98 ± 10.09 years. The HR-HPV infection in the three regions ranged from 26.16% to 43.26% with 35.42% as overall prevalence in women. The most common HR-HPV genotypes in descending order were: HPV 56, 52, 66, 59, 39, 51, 18, 35. The prevalence of bivalent vaccine genotypes (HPV16 / 18) was 7.83% against 63.78% of genotypes not covered by HPV vaccine; 36.32% (170/468) of women had multiple concomitant HR-HPV infections. Conclusion this study showed significant regional variation and high prevalence of HR-HPV infection in women. The predominant genotypes differ from those covered by available vaccines in Burkina Faso. These results will help guide our health policies towards better prevention of cervical cancer. The diversity of oncogenic genotypes is sparking a large-scale study in the West African sub-region, particularly in cases of cancer and the introduction of the nonavalent vaccine which includes HPV 52 found among the predominant genotypes in this study.
Collapse
Affiliation(s)
- Rogomenoma Alice Ouedraogo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, Ouagadougou Burkina Faso
| | - Théodora Mahoukèdè Zohoncon
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, Ouagadougou Burkina Faso
- Faculty of Medicine, University Saint Thomas d'Aquin, 06 BP 10212 Ouagadougou 01, Ouagadougou Burkina Faso
| | - Ina Marie Angèle Traore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, Ouagadougou Burkina Faso
| | - Abdoul Karim Ouattara
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, Ouagadougou Burkina Faso
| | - Sindimalgdé Patricia Guigma
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso
- Faculty of Medicine, University Saint Thomas d'Aquin, 06 BP 10212 Ouagadougou 01, Ouagadougou Burkina Faso
| | - Florencia Wendkuuni Djigma
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, Ouagadougou Burkina Faso
| | - Dorcas Obiri-Yeboah
- University of Cape Coast, School of Medical Sciences, Department of Microbiology and Immunology, University Post Office, Cape Coast Ghana
| | - Charlemagne Ouedraogo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso
- Obstetrician-gynecologist, UFR/SDS, University of Ouagadougou, 03 BP 7021 Ouagadougou 03 Ouagadougou Burkina Faso
- Yalgado Ouedraogo University Hospital (CHU/YO), 03 BP 7022, Ouagadougou Burkina Faso
| | - Jacques Simpore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, Ouagadougou Burkina Faso
- Faculty of Medicine, University Saint Thomas d'Aquin, 06 BP 10212 Ouagadougou 01, Ouagadougou Burkina Faso
| |
Collapse
|
13
|
Ouedraogo SY, Tchelougou D, Kologo JK, Sombie HK, Zeye MMJ, Compaore RT, Ouattara AK, Sorgho AP, Obiri-Yeboah D, Soubeiga ST, Nagabila I, Yonli AT, Djigma FW, Simpore J. No correlation between the variants of exostosin 2 gene and type 2 diabetes in Burkina Faso population. J Public Health Afr 2020; 11:1233. [PMID: 33209235 PMCID: PMC7649729 DOI: 10.4081/jphia.2020.1233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Accepted: 05/06/2020] [Indexed: 11/23/2022] Open
Abstract
Recent genome-wide association studies and replication analyses have reported the association of variants of the exostosin- 2 gene (EXT2) and risk of type 2 diabetes (T2D) in some populations, but not in others. This study aimed to characterize the variants rs1113132, rs3740878 and rs11037909 of EXT2 and to determine the existence of a possible correlation with T2D in Burkina Faso. It is a case-control study undertaken in Burkina Faso in the city of Ouagadougou at the Hospital of Saint Camille of Ouagadougou from December 2014 to June 2015. It relates to 121 type 2 diabetes cases and 134 controls. The genotyping of these polymorphisms was done by real-time PCR using the allelic exclusion method with TaqMan probes. The minor allele frequencies (MAFs) was almost identical in diabetic and control subjects for the all three Single Nucleotide Polymorphisms (SNPs) with no statistical significance, p>0.05: rs1113132 (OR=0.89; p=0.82); rs11037909 (OR=0.89; p=0.74) and rs3740878 (OR=1.52; p=0.42). None of the three polymorphisms studied was associated with the risk of DT2. However, an association between the BMI, age and type 2 diabetes was noted. The variants of EXT2 would not be associated to the risk of T2D in the African black population of Burkina Faso.
Collapse
Affiliation(s)
| | - Daméhan Tchelougou
- Laboratory of Molecular Biology and Genetic (LABIOGENE), Ouagadougou, Burkina Faso
| | | | - Herman Karim Sombie
- Laboratory of Molecular Biology and Genetic (LABIOGENE), Ouagadougou, Burkina Faso
| | | | - Rebeca Tégwindé Compaore
- Laboratory of Molecular Biology and Genetic (LABIOGENE), Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou
| | | | | | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana
| | | | | | - Albert Théophane Yonli
- Laboratory of Molecular Biology and Genetic (LABIOGENE), Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou
| | - Florencia Wendkuuni Djigma
- Laboratory of Molecular Biology and Genetic (LABIOGENE), Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou
| | | |
Collapse
|
14
|
Sombié HK, Sorgho AP, Kologo JK, Ouattara AK, Yaméogo S, Yonli AT, Djigma FW, Tchelougou D, Somda D, Kiendrébéogo IT, Bado P, Nagalo BM, Nagabila Y, Adoko ETHD, Zabsonré P, Millogo H, Simporé J. Glutathione S-transferase M1 and T1 genes deletion polymorphisms and risk of developing essential hypertension: a case-control study in Burkina Faso population (West Africa). BMC Med Genet 2020; 21:55. [PMID: 32188413 PMCID: PMC7081581 DOI: 10.1186/s12881-020-0990-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Accepted: 03/02/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND Glutathione S-transferases play a key role in the detoxification of persistent oxidative stress products which are one of several risks factors that may be associated with many types of disease processes such as cancer, diabetes, and hypertension. In the present study, we characterize the null genotypes of GSTM1 and GSTT1 in order to investigate the association between them and the risk of developing essential hypertension. METHODS We conducted a case-control study in Burkina Faso, including 245 subjects with essential hypertension as case and 269 control subjects with normal blood pressure. Presence of the GSTT1 and GSTM1 was determined using conventional multiplex polymerase chain reaction followed by gel electrophoresis analysis. Biochemical parameters were measured using chemistry analyzer CYANExpert 130. RESULTS Chi-squared test shows that GSTT1-null (OR = 1.82; p = 0.001) and GSTM1-active/GSTT1-null genotypes (OR = 2.33; p < 0.001) were significantly higher in cases than controls; the differences were not significant for GSTM1-null, GSTM1-null/GSTT1-active and GSTM1-null/GSTT1-null (p > 0.05). Multinomial logistic regression revealed that age ≥ 50 years, central obesity, family history of hypertension, obesity, alcohol intake and GSTT1 deletion were in decreasing order independent risk factors for essential hypertension. Analysis by gender, BMI and alcohol showed that association of GSTT1-null with risk of essential hypertension seems to be significant when BMI < 30 Kg/m2, in non-smokers and in alcohol users (all OR ≥ 1.77; p ≤ 0.008). Concerning GSTT1, GSTM1 and cardiovascular risk markers levels in hypertensive group, we found that subjects with GSTT1-null genotype had higher waist circumference and higher HDL cholesterol level than those with GSTT1-active (all p < 0.005), subjects with GSTM1-null genotype had lower triglyceride than those with GSTM1-active (p = 0.02) and subjects with the double deletion GSTM1-null/GSTT1-null had higher body mass index, higher waist circumference and higher HDL cholesterol than those with GSTM1-active/GSTT1-active genotype (all p = 0.01). CONCLUSION Our results confirm that GSTT1-null genotype is significantly associated with risk of developing essential hypertension in Burkinabe, especially when BMI < 30 Kg/m2, in non-smokers and in alcohol users, and it showed that the double deletion GSTM1-null/GSTT1-null genotypes may influence body lipids repartition.
Collapse
Affiliation(s)
- Herman Karim Sombié
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Abel Pegdwendé Sorgho
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Jonas Koudougou Kologo
- Saint Camille Hospital of Ouagadougou (HOSCO), 01 P.O. Box 444, Ouagadougou 01, Burkina Faso.,University Hospital Center-Yalgado Ouédraogo (CHUYO), 01 P.O. Box 676, Ouagadougou, Burkina Faso
| | - Abdoul Karim Ouattara
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso. .,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso.
| | - Sakinata Yaméogo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Albert Théophane Yonli
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Daméhan Tchelougou
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Dogfounianalo Somda
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | | | - Prosper Bado
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Bolni Marius Nagalo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Youssoufou Nagabila
- Saint Camille Hospital of Ouagadougou (HOSCO), 01 P.O. Box 444, Ouagadougou 01, Burkina Faso
| | | | - Patrice Zabsonré
- University Hospital Center-Yalgado Ouédraogo (CHUYO), 01 P.O. Box 676, Ouagadougou, Burkina Faso
| | - Hassanata Millogo
- Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Jacques Simporé
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph Ki-Zerbo, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Saint Camille Hospital of Ouagadougou (HOSCO), 01 P.O. Box 444, Ouagadougou 01, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso.,Faculty of Medicine, University Saint Thomas d'Aquin, P.O. Box 10212, Ouagadougou, Burkina Faso
| |
Collapse
|
15
|
Sorgho PA, Djigma FW, Martinson JJ, Yonli AT, Nagalo BM, Compaore TR, Diarra B, Sombie HK, Simpore A, Zongo AW, Ouattara AK, Soubeiga STR, Traore L, Yelemkoure ET, Kiendrebeogo IT, Roberts LR, Simpore J. Role of Killer cell immunoglobulin-like receptors (KIR) genes in stages of HIV-1 infection among patients from Burkina Faso. Biomol Concepts 2019; 10:226-236. [PMID: 31863692 DOI: 10.1515/bmc-2019-0024] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Accepted: 11/14/2019] [Indexed: 12/16/2022] Open
Abstract
Objectives A cluster of specialized KIR genes of specialized KIR genes has been shown to be associated with susceptibility or resistance to viral infections in humans. Therefore, this pilot study, this pilot investigation sought to determine the frequencies of KIR genes human immunodeficiency virus type 1( HIV-1) patients and establish their potential clinical involvement in disease progression and staging. Methods HIV-1 infected and healthy individuals were selected for this study. Hepatitis B surface antigen (HBsAg), anti-HCV antibodies and anti-HIV-1/2 antibody/ antigen were screened using a 4th generation ELISA assay (Cobas e 411 Analyzer, Roche Diagnostics GmbH Mannheim, Germany). SSP-PCR was used to evaluate the frequencies of KIR genes. CD4+ T counts and HIV-1 viral load were measured in patients using respectively BD FACSCount and Abbott m2000rt instruments. Results We found a significant association between the frequencies of KIR2DL2 (OR=4.41; p < 0.001), KIR2DS2 (OR=4.76; p < 0.001), KIR2DS3 (OR=2.27; p=0.004), KIR2DS4 (OR=1.76; p=0.026), KIR3DS1 (OR=2.43; p=0.016) and HIV-1 infection; whilst the KIR3DL1 gene (OR= 0.39; p < 0.001) was associated with protection against HIV-1 infection. HIV-1 replication was found to be associated with the presence of KIR2DS2 (OR=6.08, p = 0.024). In contrary the pseudogene KIR2DP1 (OR=0.39; p=0.026) were linked to a protective status with the highest number of lymphocyte T CD4 counts. Conclusion Our data showed that KIR2DL2, KIR2DS2, KIR2DS3, KIR2DS4, and KIR3DS1 were significantly associated with HIV-1 infection whereas KIR3DL1 was associated with protection against HIV-1 infection. Further investigations are needed to fully comprehend the clinical significance of KIR genes in HIV disease progression.
Collapse
Affiliation(s)
- Pegdwendé Abel Sorgho
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Jeremy James Martinson
- Laboratory of Infectious Diseases/ Microbiology, University of Pittsburgh, Pittsburgh, USA
| | - Albert Théophane Yonli
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Bolni Marius Nagalo
- Division of Hematology & Oncology, Mayo Clinic, Arizona, Scottsdale Arizona, USA
| | - Tégwindé Rebeca Compaore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Institut de Recherche en Sciences de la Sante, IRSS, Ouagadougou, Burkina Faso
| | - Birama Diarra
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Herman Karim Sombie
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Abibou Simpore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Arsène Wendpagnangdé Zongo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Abdoul Karim Ouattara
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Serge Théophile R Soubeiga
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Lassina Traore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| | - Edwige T Yelemkoure
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Isabelle Touwendpoulimdé Kiendrebeogo
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso
| | - Lewis R Roberts
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota,USA
| | - Jacques Simpore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
| |
Collapse
|
16
|
Ghoma Linguissi LS, Sagna T, Soubeiga ST, Gwom LC, Nkenfou CN, Obiri-Yeboah D, Ouattara AK, Pietra V, Simpore J. Prevention of mother-to-child transmission (PMTCT) of HIV: a review of the achievements and challenges in Burkina-Faso. HIV AIDS (Auckl) 2019; 11:165-177. [PMID: 31440104 PMCID: PMC6664853 DOI: 10.2147/hiv.s204661] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/09/2019] [Accepted: 06/14/2019] [Indexed: 11/23/2022]
Abstract
Background Burkina-Faso's HIV/AIDS program is one of the most successful in Africa, with a declining HIV prevalence and treatment outcomes that rival those of developed countries. Prevention of mother-to-child transmission (PMTCT) guidelines in Burkina-Faso, initiated in the year 2000, were revised in 2004, 2006 and 2010. The guideline document has since undergone several stages of improvement, largely based on recommendations from WHO, with adaptations by local experts in the field. Option B+ adopted since August 2014 in Burkina-Faso has enabled maintenance of mothers on longer treatment and increasing their survival and that of their children. Through this review, we describe the achievements and challenges of HIV PMTCT programs in Burkina-Faso. Aims of study This study had the following objectives: 1) describing the historical perspective of PMTCT implementation in Burkina-Faso; 2) presenting the effectiveness of interventions at improving PMTCT service delivery and promoting retention of mothers and babies in care; and 3) determining the impact of male partner involvement on PMTCT in Burkina-Faso. Methodology A literature search was conducted in PubMed and Google. Search terms included the following keywords: "HIV testing"; "prevention"; "mother"; "child"; "male partner"; "counseling"; "involvement"; "participation"; and the grouped terms "PMTCT and partners"; "VCT"; "barriers and/or factors"; "Male involvement in PMTCT"; and "Burkina-Faso". Data collection took place from May to October 2015. The search was limited to articles published between January 2002 and December 2015. UNICEF and UNAIDS web sites were also used to find relevant abstracts and documents. Results Studies have revealed that with PMTCT, HIV transmission rate moved from 10.4% in 2006 to 0% in 2015. The PMTCT program remains the best way to care for HIV-infected pregnant women and their babies. The current PMTCT policy is based on evidence that male partner involvement is associated with women's completion of PMTCT. Conclusion This study shows that the reduction in mother to child transmission of HIV in Burkina-Faso over the years is mainly due to the improvement of PMTCT programs. Efforts still need to be made about the involvement of male partners.
Collapse
Affiliation(s)
- Laure Stella Ghoma Linguissi
- Laboratoire de Biologie Moléculaire et de Génétique, Université Ouaga I Pr Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Institut National de Recherche en Sciences de la Santé (IRSSA), Brazzaville, Republic of Congo
| | - Tani Sagna
- Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, Burkina Faso.,Centre de Recherche Biomoleculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Serge Théophile Soubeiga
- Laboratoire de Biologie Moléculaire et de Génétique, Université Ouaga I Pr Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Centre de Recherche Biomoleculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Luc Christian Gwom
- "Chantal Biya" International Reference Centre for Research on HIV/Aids Prevention and Management (CBIRC), Yaoundé, Cameroon
| | - Céline Nguefeu Nkenfou
- Higher Teachers' Training College, University of Yaoundé I, Yaoundé, Cameroon.,"Chantal Biya" International Reference Centre for Research on HIV/Aids Prevention and Management (CBIRC), Yaoundé, Cameroon
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Abdoul Karim Ouattara
- Laboratoire de Biologie Moléculaire et de Génétique, Université Ouaga I Pr Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Centre de Recherche Biomoleculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Virginio Pietra
- Centre de Recherche Biomoleculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Jacques Simpore
- Laboratoire de Biologie Moléculaire et de Génétique, Université Ouaga I Pr Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.,Centre de Recherche Biomoleculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| |
Collapse
|
17
|
Sombié HK, Kologo JK, Tchelougou D, Ouédraogo SY, Ouattara AK, Compaoré TR, Nagalo BM, Sorgho AP, Nagabila I, Soubeïga ST, Djigma FW, Yonli AT, Zabsonré P, Millogo H, Simporé J. Positive association between ATP2B1 rs17249754 and essential hypertension: a case-control study in Burkina Faso, West Africa. BMC Cardiovasc Disord 2019; 19:155. [PMID: 31242870 PMCID: PMC6595568 DOI: 10.1186/s12872-019-1136-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2019] [Accepted: 06/12/2019] [Indexed: 01/06/2023] Open
Abstract
Background Genetic and environment play a significant role in the etiology of essential hypertension (EH). Recently STK39 rs3754777, ATP2B1 rs2681472 and rs17249754 have been associated with BP variation and hypertension. In this study we aimed to determine firstly whether index variants were associated with the risk of developing EH in Burkina Faso and secondly to characterize cardiovascular risk markers. Methods We conducted a case-control study with 380 participants including 180 case subjects with EH and 200 control subjects with normal BP. We used TaqMan genotyping assays with probes from Applied Biosystems to genotype polymorphisms using the 7500 Real-Time PCR System. Biochemical parameters were measured using chemistry analyzer COBAS C311. Results T-test showed that cardiovascular risk markers such as body mass index, waist circumference, blood sugar, total cholesterol and triglycerides were significantly higher in hypertensive compared to normotensive (all p < 0.05). Binary logistic regression analysis revealed in decreasing order that overweight, family history of hypertension, central obesity and alcohol intake increased the risk of developing EH (all OR > 3.8; all p < 0.001). In genetic level we observed that individuals carrying the AA+AG genotype of ATP2B1 rs17249754 had a low risk of developing EH than those carrying the GG genotype (OR = 0.48 [95% CI: 0.31–0.75] p = 0.001) and the A allele frequency in the cases was significantly lower than that of the controls (OR = 0.56 [95% CI: 0.38–0.82] p = 0.003). We also observed that ATP2B1 rs17249754 was significantly associated with higher SBP and DPB in case and control groups (GG versus AG + AA; p < 0.05), ATP2B1 rs2681472 was significantly associated with higher SBP only in case and control group (AA versus AG + GG; p < 0.05), STK39 rs3754777 was not significantly associated with any of the BP traits (CC versus CT + TT; p > 0.05). Conclusion Our results confirmed the significant association of ATP2B1 rs17249754 with the risk of developing EH in Burkinabe and showed an increase of cardiovascular risk markers levels in subjects with EH. Electronic supplementary material The online version of this article (10.1186/s12872-019-1136-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Herman Karim Sombié
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Jonas Koudougou Kologo
- Saint Camille hospital in Ouagadougou (HOSCO), Burkina Faso, P.O. Box 444, Ouagadougou 01, Burkina Faso
| | - Daméhan Tchelougou
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Serge Yannick Ouédraogo
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Abdoul Karim Ouattara
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Tegwindé Rebecca Compaoré
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Bolni Marius Nagalo
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Abel Pegdwendé Sorgho
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Issoufou Nagabila
- Saint Camille hospital in Ouagadougou (HOSCO), Burkina Faso, P.O. Box 444, Ouagadougou 01, Burkina Faso
| | - Serge Théophile Soubeïga
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso. .,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso.
| | - Albert Théophane Yonli
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Patrice Zabsonré
- University Hospital Center-Yalgado Ouedraogo (CHUYO), Ouagadougou, Burkina Faso
| | - Hassanata Millogo
- Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Jacques Simporé
- Department of Microbiology and Biochemistry, Laboratory of Molecular Biology and Genetics (LABIOGENE), University Ouaga I Prof. Joseph Ki-Zerbo, P.O. Box 7021, Ouagadougou 03, Burkina Faso.,Saint Camille hospital in Ouagadougou (HOSCO), Burkina Faso, P.O. Box 444, Ouagadougou 01, Burkina Faso.,Pietro Annigoni Biomolecular Research Center (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso.,Faculty of Medicine, University Saint Thomas d'Aquin, P.O. Box 10212, Ouagadougou, Burkina Faso
| |
Collapse
|
18
|
Salah FD, Soubeiga ST, Ouattara AK, Sadji AY, Metuor-Dabire A, Obiri-Yeboah D, Banla-Kere A, Karou S, Simpore J. Distribution of quinolone resistance gene ( qnr) in ESBL-producing Escherichia coli and Klebsiella spp. in Lomé, Togo. Antimicrob Resist Infect Control 2019; 8:104. [PMID: 31244995 PMCID: PMC6582466 DOI: 10.1186/s13756-019-0552-0] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Accepted: 06/04/2019] [Indexed: 11/26/2022] Open
Abstract
Background Qnr genes are known to confer a low-level resistance to fluoroquinolone in Enterobacteriaceae. They are often found on the same resistance plasmids as extended spectrum β-lactamase (ESBL) and constitute the most common antibiotic resistance mechanism. This study aimed to detect the presence of qnr genes in ESBL-producing E. coli and Klebsiella spp. Methods From May 2013 to July 2015, 91 E. coli and 64 Klebsiella spp. strains with phenotypic resistance to quinolone were collected from several specimens and analyzed for the detection of qnrA, qnrB, qnrS genes and the β-lactamase resistance genes (blaCTX-M, blaTEM, blaSHV) using simplex and multiplex PCR. Results In the present study, 107 (69%; 61 E. coli and 46 Klebsiella spp.) of 155 bacterial strains tested were found harboring at least one qnr gene consisting of 74 (47.74%) qnrB, 73 (47.10%) qnrS and 4 (2.58%) qnrA. Of the 107 strains encoding qnr genes, 102, 96 and 52 carried CTX-M1, TEM and SHV type ESBL respectively. Conclusion This study identified quinolone resistance (qnr) gene in ESBL-producing E. coli and Klebsiella spp. in Togo. These finding which suggest a possible resistance to quinolone are of high interest for better management of patients and control of antimicrobial resistance in Togo. Electronic supplementary material The online version of this article (10.1186/s13756-019-0552-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Fortune Djimabi Salah
- Biomolecular and Genetic Laboratory (LABIOGENE), Pietro Annigoni Biomolecular Research Center (CERBA), Department of Biochemistry-Microbiology, University Ouaga I Prof Joseph Ki Zerbo, BP 364, Ouagadougou, Burkina Faso.,Bacteriology Laboratory, National Institute of Hygiene (INH), BP 1396, Lomé, Togo
| | - Serge Théophile Soubeiga
- Biomolecular and Genetic Laboratory (LABIOGENE), Pietro Annigoni Biomolecular Research Center (CERBA), Department of Biochemistry-Microbiology, University Ouaga I Prof Joseph Ki Zerbo, BP 364, Ouagadougou, Burkina Faso
| | - Abdoul Karim Ouattara
- Biomolecular and Genetic Laboratory (LABIOGENE), Pietro Annigoni Biomolecular Research Center (CERBA), Department of Biochemistry-Microbiology, University Ouaga I Prof Joseph Ki Zerbo, BP 364, Ouagadougou, Burkina Faso
| | - Adodo Yao Sadji
- Bacteriology Laboratory, National Institute of Hygiene (INH), BP 1396, Lomé, Togo
| | - Amana Metuor-Dabire
- Biomolecular and Genetic Laboratory (LABIOGENE), Pietro Annigoni Biomolecular Research Center (CERBA), Department of Biochemistry-Microbiology, University Ouaga I Prof Joseph Ki Zerbo, BP 364, Ouagadougou, Burkina Faso
| | - Dorcas Obiri-Yeboah
- 4Department of Microbiology and Immunology, School of Medical Sciences, University of cape Coast, PMB, Cape Coast, Ghana
| | - Abiba Banla-Kere
- Bacteriology Laboratory, National Institute of Hygiene (INH), BP 1396, Lomé, Togo
| | - Simplice Karou
- 3High School of Biological and Food Techniques (ESTBA), University of Lomé, BP 1515, Lomé, Togo
| | - Jacques Simpore
- Biomolecular and Genetic Laboratory (LABIOGENE), Pietro Annigoni Biomolecular Research Center (CERBA), Department of Biochemistry-Microbiology, University Ouaga I Prof Joseph Ki Zerbo, BP 364, Ouagadougou, Burkina Faso
| |
Collapse
|
19
|
Yooda AP, Sawadogo S, Soubeiga ST, Obiri-Yeboah D, Nebie K, Ouattara AK, Diarra B, Simpore A, Yonli YD, Sawadogo AG, Drabo BE, Zalla S, Siritié AP, Nana RS, Dahourou H, Simpore J. Residual risk of HIV, HCV, and HBV transmission by blood transfusion between 2015 and 2017 at the Regional Blood Transfusion Center of Ouagadougou, Burkina Faso. J Blood Med 2019; 10:53-58. [PMID: 30774493 PMCID: PMC6362960 DOI: 10.2147/jbm.s189079] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Introduction In sub-Saharan Africa, the high endemicity of blood-borne infections is a serious threat to transfusion safety. In order to improve transfusion safety, Burkina Faso has undertaken in recent years a reorganization of its blood-transfusion system through the creation of a National Blood Transfusion Center, which is the only blood operator in the whole country. This study aimed to estimate the residual risk of transmission of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) by blood transfusion at the Regional Blood Transfusion Center (RBTC) of Ouagadougou. Methods This was a retrospective study conducted at the RBTC of Ouagadougou between 2015 and 2017. Prevalence of infectious markers was calculated for first-time donors and incidence rates calculated for repeat donors who had made at least two donations of blood over the study period. Residual risks were estimated for the three viruses (HIV, HBV, and HCV) by multiplying the incidence rate per 100,000 person-years by the respective durations of serological windows. Results Between 2015 and 2017, of a total of 84,299 blood donors, 68,391 (81.13%) were first-time donors compared to 15,908 (18.87%) repeat donors. The seroprevalence of HBV (8.56%) was twice that of HCV (4.40%) and fourfold that of HIV (1.80%). Incidence rates were 1,215, 2,601, and 1,599 per 100,000 donations for HIV, HCV, and HBV, respectively. In contrast, the estimated residual risk for HCV (1 in 213 donations) was double that of HBV (1 in 408 donations) and four times that of HIV (1 in 1,366). Conclusion The residual risk of transmission of these viruses by blood transfusion remains high in repeat donors. An effective donor-retention and education policy could help to reduce this residual risk.
Collapse
Affiliation(s)
- Arzouma Paul Yooda
- Laboratory of Molecular Biology and Genetics (LaBioGene), Training and Research Unit in Life and Earth Sciences, University Ouaga I Professor Joseph Ki-Zerbo, Ouagadougou, Burkina Faso, .,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso, .,National Blood Transfusion Center (NBTC), Ouagadougou, Burkina Faso
| | - Salam Sawadogo
- National Blood Transfusion Center (NBTC), Ouagadougou, Burkina Faso
| | - Serge Théophile Soubeiga
- Laboratory of Molecular Biology and Genetics (LaBioGene), Training and Research Unit in Life and Earth Sciences, University Ouaga I Professor Joseph Ki-Zerbo, Ouagadougou, Burkina Faso, .,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso,
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana
| | | | - Abdoul Karim Ouattara
- Laboratory of Molecular Biology and Genetics (LaBioGene), Training and Research Unit in Life and Earth Sciences, University Ouaga I Professor Joseph Ki-Zerbo, Ouagadougou, Burkina Faso, .,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso,
| | - Birama Diarra
- Laboratory of Molecular Biology and Genetics (LaBioGene), Training and Research Unit in Life and Earth Sciences, University Ouaga I Professor Joseph Ki-Zerbo, Ouagadougou, Burkina Faso, .,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso,
| | - Abibou Simpore
- National Blood Transfusion Center (NBTC), Ouagadougou, Burkina Faso
| | | | | | - Bia Emile Drabo
- National Blood Transfusion Center (NBTC), Ouagadougou, Burkina Faso
| | - Seimbou Zalla
- National Blood Transfusion Center (NBTC), Ouagadougou, Burkina Faso
| | | | | | | | - Jacques Simpore
- Laboratory of Molecular Biology and Genetics (LaBioGene), Training and Research Unit in Life and Earth Sciences, University Ouaga I Professor Joseph Ki-Zerbo, Ouagadougou, Burkina Faso, .,Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso,
| |
Collapse
|
20
|
Yelemkoure ET, Yonli AT, Montesano C, Ouattara AK, Diarra B, Zohoncon TM, Nadembega CWM, Ouedraogo P, Sombié C, Soubeiga ST, Tao I, Gansane A, Amicosante M, Djigma F, Obiri-Yeboah D, Pietra V, Simpore J, Colizzi V. Prevention of mother-to-child transmission of hepatitis B virus in Burkina Faso: Screening, vaccination and evaluation of post-vaccination antibodies against hepatitis B surface antigen in newborns. J Public Health Afr 2018; 9:816. [PMID: 30687485 PMCID: PMC6326159 DOI: 10.4081/jphia.2018.816] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Accepted: 08/09/2018] [Indexed: 01/06/2023] Open
Abstract
The low rate of screening for hepatitis B virus (HBV) in pregnant women is a highrisk factor for its vertical transmission. The objectives of this study were: i) to screen pregnant women for HBV infection; ii) vaccinate all children from birth against HBV regardless their mother HBV status; and iii) evaluate after 7 months of birth the level of their AbHBs among babies who received HBV vaccine at birth. Serological markers of HBV (HBsAg, HBeAg, AbHBs, AbHBe, and AbHBc) were determined on venous blood samples from 237 pregnant women and their children using the Abon Biopharm Kit. One hundred and two (102) children received the three doses of the EUVAX B® vaccine respectively at birth, two months and four months of life. Seven months after delivery, venous blood samples were collected from mothers and their children. Antibodies against hepatitis B surface antigen (AbHBs) were measured in vaccinated children using the ELISA Kit AbHBs Quantitative EIA. DNA extraction was performed on samples from HBV-seropositive mothers and their children using the Ribo Virus (HBV Real-TM Qual) Kit and for Real Time PCR, the HBV Real-TM Qual Kit was used. Serological diagnosis in pregnant women revealed 22 (9.28%) hepatitis B surface antigen (HBsAg) positive samples of which 21 were positive for viral DNA by real-time PCR. Among the 22 HBsAg+ women, five (05) transmitted the virus to their children with a vertical transmission rate of 22.73%. A transmission rate of 23.81% (5/21) was found with the PCR method. Analysis of AbHBs levels revealed that 98.31% of the children had an average concentration of 218.07 ± 74.66 IU/L, which is well above the minimum threshold for protection (11 IU/L). This study has confirmed that vertical transmission of HBV is a reality in Burkina Faso and that vaccination at birth would significantly reduce this transmission.
Collapse
Affiliation(s)
- Edwige T Yelemkoure
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Albert T Yonli
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Carla Montesano
- Department of Biology, Tor Vergata University of Rome, Italy
| | - Abdoul Karim Ouattara
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Birama Diarra
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Théodora M Zohoncon
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Christelle W M Nadembega
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso
| | - Paul Ouedraogo
- Saint Camille Hospital of Ouagadougou (HOSCO), Burkina Faso
| | - Charles Sombié
- Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Serge Theophile Soubeiga
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Issoufou Tao
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso
| | - Adama Gansane
- Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
| | | | - Florencia Djigma
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana
| | - Virginio Pietra
- Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
| | - Jacques Simpore
- Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.,Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.,Department of Biology, Tor Vergata University of Rome, Italy
| | | |
Collapse
|
21
|
Compaore TR, Soubeiga ST, Ouattara AK, Tchelougou D, Bisseye C, Bakouan DR, Compaore I, Dembele A, Yonli AT, Obiri-Yeboah D, Djigma WF, Simpore J. APOBEC3G expression and HIV-1 infection in Burkina Faso. J Public Health Afr 2018; 9:907. [PMID: 30687488 PMCID: PMC6326155 DOI: 10.4081/jphia.2018.907] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 08/14/2018] [Indexed: 11/23/2022] Open
Abstract
APOBEC3G is a potent inhibitor of HIV-1 replication, and act by deaminating cytidines in uracil on the negative strand of the viral cDNA. In this case-control study, APOBEC3G expression in subjects' naïve to HAART infected by HIV-1 and the effect of APOBEC3G polymorphism on its expression were evaluated. The results show that the HIV-1 infected carriers of the G minor alleles of the variant rs8177832 had a higher expression of APOBEC3G mRNA than the controls carriers of the G minor allele. APOBEC3G polymorphisms could play an important role in the modulation of the HIV-1 dissemination.
Collapse
Affiliation(s)
- Tegwinde Rebeca Compaore
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Burkina Faso
| | - Serge Theophile Soubeiga
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Burkina Faso
| | - Abdoul Karim Ouattara
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Burkina Faso
| | - Damehan Tchelougou
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Burkina Faso
| | - Cyrille Bisseye
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Burkina Faso
| | - Didier Romuald Bakouan
- Permanent Secretary Against Aids and Sexually Transmitted Diseases, Ouagadougou, Burkina Faso
| | - Issaka Compaore
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Burkina Faso
| | - Augustine Dembele
- Permanent Secretary Against Aids and Sexually Transmitted Diseases, Ouagadougou, Burkina Faso
| | - Albert Theophane Yonli
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Microbiology Department, School of Medical Sciences, University of Cape Coast, Ghana
| | | | - Jacques Simpore
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Burkina Faso
| |
Collapse
|
22
|
Assih M, Ouattara AK, Diarra B, Yonli AT, Compaore TR, Obiri-Yeboah D, Djigma FW, Karou S, Simpore J. Genetic diversity of hepatitis viruses in West-African countries from 1996 to 2018. World J Hepatol 2018; 10:807-821. [PMID: 30533182 PMCID: PMC6280160 DOI: 10.4254/wjh.v10.i11.807] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Revised: 09/10/2018] [Accepted: 10/23/2018] [Indexed: 02/06/2023] Open
Abstract
The severity of hepatic pathology and the response to treatment depend on the hepatitis virus genotype in the infected host. The objective of this review was to determine the distribution of hepatitis virus genotypes in West African countries. A systematic review of the literature in PubMed, Google Scholar and Science Direct was performed to identify 52 relevant articles reporting hepatitis A, B, C, D, E and G viruses genotypes. Hepatitis B virus (HBV) genotype E with a prevalence of 90.6% (95%CI: 0.891-0.920) found in this review, is characterized by low genetic diversity. Hepatitis C virus (HCV) genotypes 1 and 2 represented 96.4% of HCV infections in West African countries, while hepatitis delta virus, hepatitis A virus, hepatitis G virus genotypes 1 and HEV genotype 3 were reported in some studies in Ghana and Nigeria. HBV genotype E is characterized by high prevalence, low genetic diversity and wide geographical distribution. Further studies on the clinical implications of HBV genotype E and HCV genotypes 1 and 2 are needed for the development of an effective treatment against this viral hepatitis in West African countries. Surveillance of the distribution of different genotypes is also needed to reduce recombination rates and prevent the emergence of more virulent viral strains.
Collapse
Affiliation(s)
- Maléki Assih
- Biochemistry-Microbiology, CERBA/LABIOGENE, Ouagadougou 02006, Burkina Faso
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 00226, Burkina Faso
| | - Abdoul Karim Ouattara
- Biochemistry-Microbiology, CERBA/LABIOGENE, Ouagadougou 02006, Burkina Faso
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 00226, Burkina Faso
| | - Birama Diarra
- Biochemistry-Microbiology, CERBA/LABIOGENE, Ouagadougou 02006, Burkina Faso
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 00226, Burkina Faso
| | - Albert Theophane Yonli
- Biochemistry-Microbiology, CERBA/LABIOGENE, Ouagadougou 02006, Burkina Faso
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 00226, Burkina Faso
| | - Tegwindé Rebeca Compaore
- Biochemistry-Microbiology, CERBA/LABIOGENE, Ouagadougou 02006, Burkina Faso
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 00226, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Cape Coast 00233, Ghana
| | - Florencia Wendkuuni Djigma
- Biochemistry-Microbiology, CERBA/LABIOGENE, Ouagadougou 02006, Burkina Faso
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 00226, Burkina Faso
| | - Simplice Karou
- Ecole Supérieure des Techniques Biologiques et Alimentaires (ESTBA-UL), Universite de Lome, Lome 00229, Togo
| | - Jacques Simpore
- Biochemistry-Microbiology, CERBA/LABIOGENE, Ouagadougou 02006, Burkina Faso
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 00226, Burkina Faso
| |
Collapse
|
23
|
Ouédraogo NLM, Ilboudo S, Ouattara AK, Ouedraogo AS, Zida M, Zongo N, Obiri-Yeboah D, Ouangre E, Simpore J, Traore SS. A case report of Villar's nodule in a woman without surgical history. Int J Surg Case Rep 2018; 53:186-188. [PMID: 30408743 PMCID: PMC6222089 DOI: 10.1016/j.ijscr.2018.10.066] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 09/18/2018] [Accepted: 10/07/2018] [Indexed: 12/02/2022] Open
Abstract
INTRODUCTION Villar's nodule is an umbilical endometriosis without anterior or ongoing pelvic endometriosis. The primitive location of this nodule at the umbilical level is rare. Its etiopathogenesis remains unclear. PRESENTATION OF CASE We report a case of umbilical endometriosis with unusual clinical expression in a woman in the reproductive years with no surgical history and no known history of endometriosis. Endometriosis manifested as progressive transformation of the normal umbilicus into several small nodules, with bleeding coinciding with the menstrual cycle. The diagnosis was confirmed by histology and surgical treatment consisted of omphalectomy. DISCUSSION Umbilical endometriosis is a rare disease that occurs naturally in patients with pelvic endometriosis. Etiopathogenesis of the disease is still unclear. In our patient, the appearance of the nodule was impressively, by a gradual transformation of the normal aspect of the umbilicus, into several small, slightly pigmented, firm, painful and concomitantly bleeding nodules during periods of menstruation. In the literature, this multinodular or budding form would be of exceptional observation. CONCLUSION The characteristics of the umbilical tumor, associated with the cyclical nature of tumor bleeding in a patient without previous history of endometriosis, strongly suggest the diagnosis of Villar's nodule, but the confirmation is still histological. The treatment is always surgical and recurrence is very rare.
Collapse
Affiliation(s)
| | - Safy Ilboudo
- Gynecology Service of Saint Camille Hospital of Ouagadougou, 01 BP 444 Ouagadougou 01, Burkina Faso
| | - Abdoul Karim Ouattara
- Pietro Annigoni Biomolecular Research Center (CERBA)/LABIOGENE, University Ouaga 1 Prof. Joseph KI ZERBO, UFR/SVT. 03BP 7021 Ouagadougou 03, Burkina Faso
| | - Aimé Sosthène Ouedraogo
- General and Digestive Surgery Department of Yalgado Ouedraogo University Hospital Center (CHU.YO), Burkina Faso
| | - Maurice Zida
- General and Digestive Surgery Department of Yalgado Ouedraogo University Hospital Center (CHU.YO), Burkina Faso
| | - Nayi Zongo
- General and Digestive Surgery Department of Yalgado Ouedraogo University Hospital Center (CHU.YO), Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Edgard Ouangre
- General and Digestive Surgery Department of Yalgado Ouedraogo University Hospital Center (CHU.YO), Burkina Faso
| | - Jacques Simpore
- Pietro Annigoni Biomolecular Research Center (CERBA)/LABIOGENE, University Ouaga 1 Prof. Joseph KI ZERBO, UFR/SVT. 03BP 7021 Ouagadougou 03, Burkina Faso
| | - Si Simon Traore
- General and Digestive Surgery Department of Yalgado Ouedraogo University Hospital Center (CHU.YO), Burkina Faso
| |
Collapse
|
24
|
Diarra B, Yonli AT, Ouattara AK, Zohoncon TM, Traore L, Nadembega C, Obiri-Yeboah D, Yara J, Pietra V, Ouedraogo P, Bougouma A, Sanogo R, Simpore J. World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal. Virol J 2018; 15:121. [PMID: 30081915 PMCID: PMC6080359 DOI: 10.1186/s12985-018-1032-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 07/26/2018] [Indexed: 01/28/2023] Open
Abstract
Background Burkina Faso is a high endemicity country for HBV infection. However, there are few data on vaccine coverage against HBV. The aim of this study was to contribute to the improvement of HBV vaccine coverage in Ouagadougou through HBV screening. Methods Awareness campaigns and voluntary hepatitis B screening were organized in the twelve districts of Ouagadougou by the “SOS Hepatitis Burkina” association. A rapid HBsAg detection test (Abon Biopharma Guangzhou, Co., Ltd. Chine) was performed on 2216 individuals, who voluntarily answered a series of questions. Vaccination against hepatitis B was proposed to HBV negative participants. Results In a sample of 2216 participants, aged 1 to 78 years (mean age 29.7 ± 14.7 years); a prevalence of 10.4% (230/2216) of HBsAg was obtained. This prevalence was high in the age groups 31 to 40 years (14.5%) and 41 to 50 years (15.0%). The prevalence of HBV was higher in the sixth district (14.3%) of Ouagadougou. At the end of the screening, 1202/1986 HBV negative participants were vaccinated, resulting in a vaccination rate of 60.5%. Vaccination coverage ranged from 44.5 to 73.7% all twelve districts. Conclusions This study still reports a high prevalence of HBV infection among young people with a peak in the sixth district of Ouagadougou. The study achieved high vaccination coverage in all age groups and districts of Ouagadougou. Trial registration The present study has been approved by the Ethics Committee for Health Research of Burkina Faso. CERS201501006 Registered 14 January 2015.
Collapse
Affiliation(s)
- Birama Diarra
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Albert Theophane Yonli
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Abdoul Karim Ouattara
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso. .,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso.
| | - Theodora Mahoukèdè Zohoncon
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Lassina Traore
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Christelle Nadembega
- Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Justine Yara
- SOS Hepatitis, Ouagadougou, Burkina Faso.,Saint Camille Hospital of Ouagadougou (HOSCO), BP 444, Ouagadougou 01, Burkina Faso
| | - Virginio Pietra
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso
| | - Paul Ouedraogo
- Saint Camille Hospital of Ouagadougou (HOSCO), BP 444, Ouagadougou 01, Burkina Faso
| | - Alain Bougouma
- Gastroenterology Service, CHU Yalgado OUEDRAOGO, Ouagadougou, Burkina Faso
| | - Rokia Sanogo
- Faculty of Pharmacy, University of Technical Sciences and Technologies of Bamako (USTTB), Bamako, Mali
| | - Jacques Simpore
- Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso.,Saint Camille Hospital of Ouagadougou (HOSCO), BP 444, Ouagadougou 01, Burkina Faso
| |
Collapse
|
25
|
Soubeiga ST, Bazie BVJTE, Compaore TR, Ouattara AK, Zohoncon TM, Obiri-Yeboah D, Yonli AT, Zongo A, Traore L, Pietra V, Akpona S, Diagbouga S, Simpore J. Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso. J Public Health Afr 2018; 9:767. [PMID: 30079168 PMCID: PMC6057714 DOI: 10.4081/jphia.2018.767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Accepted: 02/19/2018] [Indexed: 11/23/2022] Open
Abstract
The emergence of HIV-1 drug resistance (HIVDR) is a public health problem that affects women and children. Local data of HIVDR is critical to improving their care and treatment. So, we investigated HIVDR in mothers and infants receiving antiretroviral therapy (ART) at Saint Camille Hospital of Ouagadougou, Burkina Faso. This study included 50 mothers and 50 infants on ART. CD4 and HIV-1 viral load were determined using FACSCount and Abbott m2000rt respectively. HIVDR was determined in patients with virologic failure using ViroSeq HIV-1 Genotyping System kit on the 3130 Genetic Analyzer. The median age was 37.28 years in mothers and 1.58 year in infants. Sequencing of samples showed subtypes CRF02_AG (55.56%), CRF06_cpx (33.33%) and G (11.11%). M184V was the most frequent and was associated with highlevel resistance to 3TC, FTC, and ABC. Other mutations such as T215F/Y, D67N/E, K70R, and K219Q were associated with intermediate resistance to TDF, AZT, and 3TC. No mutation to LPV/r was detected among mothers and infants. The findings of HIVDR in some mothers and infants suggested the change of treatment for these persons.
Collapse
Affiliation(s)
- Serge Théophile Soubeiga
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | | | - Tegwindé Rebeca Compaore
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Abdoul Karim Ouattara
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Théodora Mahoukèdè Zohoncon
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana
| | - Albert Théophane Yonli
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Arsène Zongo
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Lassina Traore
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | - Virginio Pietra
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| | | | - Serge Diagbouga
- Research Institute for Health Sciences, Ouagadougou, Burkina Faso
| | - Jacques Simpore
- Pietro Annigoni Biomolecular Research Centre, LABIOGENE, University Ouaga I Prof. Joseph, Ki-Zerbo, Burkina Faso
| |
Collapse
|
26
|
Bambara HA, Zouré AA, Sawadogo AY, Ouattara AK, Ouédraogo NLM, Traoré SS, Bakri Y, Simpore J. Breast cancer: descriptive profile of 80 women attending breast cancer care in the Department of General and Digestive Surgery of CHU-YO. Pan Afr Med J 2017; 28:314. [PMID: 29721144 PMCID: PMC5927573 DOI: 10.11604/pamj.2017.28.314.10203] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 12/06/2017] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION Breast cancer is a common cause of death among women in Burkina Faso. The aim of this study was to determine a descriptive profile of 80 women and establish a description of risk factors associated with breast cancer in these women. METHODS This cross-sectional study recruited women with breast cancer in Ouagadougou. Teaching Hospital Yalgado Ouedraogo in Burkina Faso from January 2015 to February 2016. We have collected data on socio-demographic characteristics, reproductive status, clinical information, treatment and molecular characteristics. RESULTS The average age of the study population was 48.2±12.4 years. Family history of breast cancer was reported in 18.75% of the studied participants against 16.25% family history for other types of cancer. Patients from urban areas represented 87.5% of our studied population with 58.75% of household, multiparous (55.0%), no aborts status (56.2%), post-menopausal women (53.75%), no oral contraception (63.75%), regular menstrual cycle (71.25%) and the prevalence of obesity was 12.5%. The clinical and molecular characteristics showed that left-sided breast cancer accounted for 51.25 %, high grade (II and III) represented 93.75 % of cases and the majority of tumors were infiltrating ductal carcinomas (93.75%) with stages III and IV accounted for 50.0%. CONCLUSION This study described the distribution of risks factors in a population of breast cancer women. Although more research are needed to support these findings, a clear understanding of risk factors associated with breast cancer would contribute to significantly reduce breast cancer incidence and mortality in Burkina Faso.
Collapse
Affiliation(s)
| | - Abdou Azaque Zouré
- Biomolecular Research Center Pietro Annigoni (CERBA)/LABIOGENE UFR/SVT, University of Ouaga 1 Pr Joseph Ki Zerbo, Ouagadougou 1, Burkina Faso
- Laboratoiry of Biochemistry and Immunology, Faculty of Sciences, University of Mohammed V, Rabat, Morocco
- Institute of Health Sciences Research, (IRSS/CNRST)/Department of Biomedical and Public Health, Burkina Faso
| | | | - Abdoul Karim Ouattara
- Biomolecular Research Center Pietro Annigoni (CERBA)/LABIOGENE UFR/SVT, University of Ouaga 1 Pr Joseph Ki Zerbo, Ouagadougou 1, Burkina Faso
| | | | - Si Simon Traoré
- Service of General Surgery and Digestive, University Hospital Yalgado Ouédraogo, Burkina Faso
| | - Youssef Bakri
- Laboratoiry of Biochemistry and Immunology, Faculty of Sciences, University of Mohammed V, Rabat, Morocco
| | - Jacques Simpore
- Biomolecular Research Center Pietro Annigoni (CERBA)/LABIOGENE UFR/SVT, University of Ouaga 1 Pr Joseph Ki Zerbo, Ouagadougou 1, Burkina Faso
| |
Collapse
|
27
|
Ouattara AK, Yameogo P, Traore L, Diarra B, Assih M, Compaore TR, Obiri-Yeboah D, Soubeiga ST, Djigma FW, Simpore J. Prevalence, genetic variants and clinical implications of G-6-PD deficiency in Burkina Faso: a systematic review. BMC Med Genet 2017; 18:139. [PMID: 29169341 PMCID: PMC5701495 DOI: 10.1186/s12881-017-0496-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/12/2017] [Accepted: 11/09/2017] [Indexed: 11/10/2022]
Abstract
BACKGROUND It is now well-known that some antimalarials such as primaquine may induce severe hemolytic anemia in people with G-6-PD deficiency. Antimalarial drug prescriptions must, therefore take into account the patient's G-6-PD status in malaria endemic areas such as Burkina Faso, where the prevalence of this genetic abnormality is relatively high. Although great clinical heterogeneity is observed depending on the molecular nature of the deficiency and the residual enzyme activity in the red blood cell, there is very poor data on the prevalence of G-6-PD deficiency and the distribution of involved genetic variants in Burkina Faso. In this systematic review, we present a synthesis of the various studies carried out on the G-6-PD deficiency in Burkina Faso in order to determine its prevalence, probable distribution of the genetic variants involved and their clinical implications for a national systematic screening policy among the groups most vulnerable to malaria. METHODS A systematic review was carried out to analyze available published data on the prevalence, phenotypes and mutations responsible for G-6-PD deficiency in Burkina Faso. The key words used were "G-6-PD deficiency AND Burkina Faso" or "Déficit en G-6-PD AND Burkina Faso" in French. To identify the relevant articles, two independent reviewers reviewed the titles, abstracts and the full text of the selected papers. RESULTS An average prevalence of 16.6% (183/1100; CI 95%: 0.145-0.190) and 6.5% (69/1066; CI 95%: 0.051-0.081) of G-6-PD deficiency was found respectively in men and women in this systematic review. Although the predominance (99.8% of G-6-PD deficient cases) of 202A/376G G-6-PD A- variant, the Santamaria and Betica Selma variants were identified in Burkina Faso. Independently of the method used, the enzymatic deficiency was significantly higher in males (2.5-20.5%) compared to females (3.3-12.3%). CONCLUSION This systematic review suggests that despite the ubiquity of the 202A/376G G-6-PD A- variant in Burkina Faso, it will be necessary to consider the Santamaria and Betica Selma variants although their frequencies remain to be specified. A systematic screening of the G-6-PD deficiency is also needed to prevent the occurrence of iatrogenic hemolytic accidents.
Collapse
Affiliation(s)
- Abdoul Karim Ouattara
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso. .,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso.
| | - Pouiré Yameogo
- Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Lassina Traore
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Birama Diarra
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Maléki Assih
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Tegwindé Rébéca Compaore
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, University of Cape Coast, Cape Coast, Ghana
| | - Serge Théophile Soubeiga
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Florencia Wendkuuni Djigma
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| | - Jacques Simpore
- Pietro Annigoni Biomolecular Research Center (CERBA), 01 PO BOX 364, Ouagadougou 01, Burkina Faso.,Laboratory of Molecular Biology and Molecular Genetics (LABIOGENE) UFR/SVT, University Ouaga I Prof Joseph KI-ZERBO, Ouagadougou 03, BP 7021, Burkina Faso
| |
Collapse
|
28
|
Zouré AA, Bambara AH, Sawadogo AY, Ouattara AK, Ouédraogo M, Traoré SS, Bakri Y, Simporé J. Multiparity and Breast Cancer Risk Factor among Women in Burkina Faso. Asian Pac J Cancer Prev 2016; 17:5095-5099. [PMID: 28122440 PMCID: PMC5454642 DOI: 10.22034/apjcp.2016.17.12.5095] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
The relative lack of information on breast cancer etiology in Burkina Faso led us to undertake the present work to highlight risk factors. This prospective study was conducted using a questionnaire between January 2015 and February 2016 on women admitted to Yalgado OUEDRAOGO hospital, for consultation or supervision. The characteristics of multiparous breast cancer patients (n = 44) were compared with their non-multiparous counterparts (n = 36). The study found that increased risk of breast cancer among non-multiparous cases was related to body mass index (BMI) (p <0.001), age at menopause (p <0.004) and use of oral contraception (p <0.021) while abortion (p <0.002) was a risk factor among multiparous cases. These results suggest that even if multiparity is associated with a decreased risk in some women, avoidance of abortion during reproductive life should be recommended. The results provide preliminary information, which now need to be supplemented by survey of a larger sample in the national territory.
Collapse
Affiliation(s)
- Abdou Azaque Zouré
- Biomolecular Research Center Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga1 Pr Joseph KI ZERBO, UFR/SVT, Burkina Faso.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Compaore TR, Diarra B, Assih M, Obiri-Yeboah D, Soubeiga ST, Ouattara AK, Tchelougou D, Bisseye C, Bakouan DR, Compaore IP, Dembele A, Djigma WF, Simpore J. HBV/HIV co-infection and APOBEC3G polymorphisms in a population from Burkina Faso. BMC Infect Dis 2016; 16:336. [PMID: 27449138 PMCID: PMC4957463 DOI: 10.1186/s12879-016-1672-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 06/16/2016] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G) is a potent host defense factor, which interferes with HIV-1 and HBV. Our study had three objectives, to screen a population of HIV-1 infected and uninfected patients in Burkina Faso for HBV, to screen the population for APOBEC3G variants rs6001417, rs8177832, and rs35228531 previously described, and to analyze the effect of these three variants and their haplotypes on HIV-1/HBV co-infection in Burkina Faso. METHODS HBV detection was performed on samples from HIV-1 infected and uninfected subjects using rapid detection tests and real-time PCR. APOBEC3 genotyping was done by the TaqMan allelic discrimination method. Fisher Exact test, Odds ratio (OR), confidence intervals (CI) at 95 %, Linkage disequilibrium (LD) summary statistics and haplotype frequencies were calculated. RESULTS The prevalence of HBV was 56.7 % among HIV-1 positive patients of our study while it was about 12.8 % among HIV-1 seronegative subjects. Genotype E was the genotype of HBV present in our hepatitis B positive samples. Minor allele frequencies of rs6001417, rs8177832, and rs35228531 were higher in seronegative subjects. The T minor allele of variant rs35228531 was protective against HIV-1/HBV co-infection with OR = 0.61, 95 % CI (0.42-0.90), p = 0.013. There was also an association between the GGT haplotype and protection against HIV-1/HBV co-infection, OR = 0.57, 95 % CI (0.33-0.99), p = 0.050. The other haplotypes present in the population were not statistically significant. There minor allele T of the rs35228531 was protective against HIV mono-infection OR = 0.53, 95 % CI (0.3-0.93), P = 0.030. But there was no effect of protection against HBV mono-infection. CONCLUSION APOBEC3G through its variants rs6001417, rs8177832, and rs35228531, in this study interferes with HIV-1/HBV co-infection could be due the HIV-1 mono-infection in a population from Burkina Faso.
Collapse
Affiliation(s)
- Tegwinde Rebeca Compaore
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Birama Diarra
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Maleki Assih
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Serge Theophile Soubeiga
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Abdoul Karim Ouattara
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Damehan Tchelougou
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Cyrille Bisseye
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Didier Romuald Bakouan
- Permanent Secretary against Aids and sexually transmitted diseases, Ouagadougou, Burkina Faso
| | - Issaka Pierre Compaore
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Augustine Dembele
- Permanent Secretary against Aids and sexually transmitted diseases, Ouagadougou, Burkina Faso
| | - Wendkuuni Florencia Djigma
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Jacques Simpore
- Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso.
| |
Collapse
|
30
|
Compaore TR, Soubeiga ST, Ouattara AK, Obiri-Yeboah D, Tchelougou D, Maiga M, Assih M, Bisseye C, Bakouan D, Compaore IP, Dembele A, Martinson J, Simpore J. APOBEC3G Variants and Protection against HIV-1 Infection in Burkina Faso. PLoS One 2016; 11:e0146386. [PMID: 26741797 PMCID: PMC4704832 DOI: 10.1371/journal.pone.0146386] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Accepted: 12/16/2015] [Indexed: 01/27/2023] Open
Abstract
Studies on host factors, particularly the APOBEC3G gene, have previously found an association with AIDS progression in some populations and against some HIV-1 strains but not others. Our study had two main objectives: firstly, to screen a population from Burkina Faso for three variants of APOBEC3G previously described, and secondly to analyze the effect of these three variants and their haplotypes on HIV-1 infection with Circulating Recombinant Forms (CRFs) present in Burkina Faso. This case control study involved 708 seropositive and seronegative individuals. Genotyping was done by the TaqMan allelic discrimination method. Minor allele frequencies of rs6001417 (p<0.05), rs8177832 (P<0.05), and rs35228531 (P<0.001) were higher in seronegative subjects. The rs6001417 and rs8177832 SNPs were associated with HIV-1 infection in an additive model (P<0.01). Furthermore the SNP rs35228531 was also associated with HIV-1 infection in a dominant model (P<0.001). Odds ratio analysis of genotypes and alleles of the different APOBEC3G variants showed that there is a strong association between the minor genetic variants, genotype of the three SNPs, and HIV-1 status. Haplotype analysis demonstrated that rs6001417, rs8177832, and rs35228531 are in linkage disequilibrium. The haplotype GGT from the rs6001417, rs8177832 and rs35228531 respectively has a protective effect OR = 0.54 [0.43-0.68] with P<0.001. There was also associations between the haplotypes GGC OR = 1.6 [1.1;-2.3] P<0.05, and CGC OR = 5.21 [2.4-11.3] P<0.001, which increase the risk of infection by HIV-1 from almost two (2) to five (5) fold. This study demonstrates an association of rs6001417, rs8177832, and rs35228531 of APOBEC3G with HIV-1 infection in a population from Burkina Faso.
Collapse
Affiliation(s)
- Tegwinde Rebeca Compaore
- Pietro Annigoni Biomolecular Research Centre (CERBA)/ LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Serge Theophile Soubeiga
- Pietro Annigoni Biomolecular Research Centre (CERBA)/ LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Abdoul Karim Ouattara
- Pietro Annigoni Biomolecular Research Centre (CERBA)/ LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Dorcas Obiri-Yeboah
- University of Cape Coast, School of Medical Sciences, Microbiology Department, Cape Coast, Ghana
| | - Damehan Tchelougou
- Pietro Annigoni Biomolecular Research Centre (CERBA)/ LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Mamoudou Maiga
- Pietro Annigoni Biomolecular Research Centre (CERBA)/ LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Maleki Assih
- Pietro Annigoni Biomolecular Research Centre (CERBA)/ LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Cyrille Bisseye
- Laboratory of Molecular and Cellular Biology, University of Sciences and Techniques of Masuku (USTM), Franceville, Gabon
| | - Didier Bakouan
- Permanent Secretary against AIDS and Sexually Transmitted Diseases, Ouagadougou, Burkina Faso
| | - Issaka Pierre Compaore
- Pietro Annigoni Biomolecular Research Centre (CERBA)/ LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Augustine Dembele
- Permanent Secretary against AIDS and Sexually Transmitted Diseases, Ouagadougou, Burkina Faso
| | - Jeremy Martinson
- Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Jacques Simpore
- Pietro Annigoni Biomolecular Research Centre (CERBA)/ LABIOGENE, University of Ouagadougou, Ouagadougou, Burkina Faso
| |
Collapse
|
31
|
Ouattara AK, Bisseye C, Bazie BVJTE, Diarra B, Compaore TR, Djigma F, Pietra V, Moret R, Simpore J. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with asymptomatic malaria in a rural community in Burkina Faso. Asian Pac J Trop Biomed 2014; 4:655-8. [PMID: 25183336 DOI: 10.12980/apjtb.4.2014apjtb-2014-0100] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2014] [Accepted: 08/21/2014] [Indexed: 01/27/2023] Open
Abstract
OBJECTIVE To investigate 4 combinations of mutations responsible for glucose-6-phosphate dehydrogenase (G6PD) deficiency in a rural community of Burkina Faso, a malaria endemic country. METHODS Two hundred individuals in a rural community were genotyped for the mutations A376G, G202A, A542T, G680T and T968C using TaqMan single nucleotide polymorphism assays and polymerase chain reaction followed by restriction fragment length polymorphism. RESULTS The prevalence of the G6PD deficiency was 9.5% in the study population. It was significantly higher in men compared to women (14.3% vs 6.0%, P=0.049). The 202A/376G G6PD A- was the only deficient variant detected. Plasmodium falciparum asymptomatic parasitaemia was significantly higher among the G6PD-non-deficient persons compared to the G6PD-deficient (P<0.001). The asymptomatic parasitaemia was also significantly higher among G6PD non-deficient compared to G6PD-heterozygous females (P<0.001). CONCLUSIONS This study showed that the G6PD A- variant associated with protection against asymptomatic malaria in Burkina Faso is probably the most common deficient variant.
Collapse
Affiliation(s)
- Abdoul Karim Ouattara
- Centre for Biomolecular Research Pietro Annigoni (CERBA) LABIOGENE UFR/SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Cyrille Bisseye
- Centre for Biomolecular Research Pietro Annigoni (CERBA) LABIOGENE UFR/SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso ; Laboratory of Molecular and Cellular Biology (LABMC), University of Science and Technology of Masuku (USTM), BP 943 Franceville, Gabon
| | | | - Birama Diarra
- Centre for Biomolecular Research Pietro Annigoni (CERBA) LABIOGENE UFR/SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Tegwindé Rebeca Compaore
- Centre for Biomolecular Research Pietro Annigoni (CERBA) LABIOGENE UFR/SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Florencia Djigma
- Centre for Biomolecular Research Pietro Annigoni (CERBA) LABIOGENE UFR/SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Virginio Pietra
- Centre for Biomolecular Research Pietro Annigoni (CERBA) LABIOGENE UFR/SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Remy Moret
- Centre for Biomolecular Research Pietro Annigoni (CERBA) LABIOGENE UFR/SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| | - Jacques Simpore
- Centre for Biomolecular Research Pietro Annigoni (CERBA) LABIOGENE UFR/SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso
| |
Collapse
|